Analyst Note
| Aaron Degagne |Exact Sciences had a good finish to the year, with reported sales in line with our expectations driven by a strong fourth-quarter result in the high-growth precision oncology business. We are maintaining our no-moat rating and $76 fair value estimate, and we still view shares as significantly overvalued.